Initiation: Golden moments
Midatech is a clinical-stage development company. Its two core technology platforms have broad applicability, offering the potential to transform the bioavailability and delivery of many existing therapeutic agents. The gold nanoparticle (GNP) platform underpins a number of clinical programmes, with the lead project being the transbuccal delivery of insulin. The polymer microsphere technology can tailor a drug’s release over extended periods. Management is proposing to acquire DARA BioSciences, a US oncology care business, in an all-share transaction for $24.0m (£15.8m). Our rNPV model, ex DARA, suggests a current value of £134.7m (485p a share).Midatech Pharma is a holding company. Through its subsidiaries, Co. is engaged as a specialty pharmaceutical company focused on the development and commercialization of multiple therapeutic products, using its nanomedicine and sustained release technologies, to enhance the delivery of medicines in major diseases with high unmet medical needs. These diseases include diabetes, certain cancers such as liver, ovarian and brain (glioblastoma) and neurological/ophthalmologic conditions. Co.'s two platform technologies are designed to enable targeted delivery and sustained release of existing therapeutic drugs to the "right place" at the "right time."
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.